Global Octreotide Acetate

Octreotide Acetate Comprehensive Study by Type (Immediate-release Injection Form, LAR Depot Form), Application (Medical Therapeutic, Medical Prophylactic), Form (Injectable, Tablets, Capsules, Others), End Use (Hospital, Specialty Clinic) Players and Region - Global Market Outlook to 2026

Octreotide Acetate Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Octreotide Acetate Market Overview:
A cyclic octapeptide's acetate salt is called octreotide. It's a long-acting octapeptide with pharmacologic properties that imitate those of the natural hormone somatostatin, and it's used to treat extreme watery diarrhea and rapid reddening of the face and neck caused by certain forms of tumors in the intestines and pancreas (e.g., carcinoid tumors, vasoactive intestinal peptide tumors). Octreotide is also used to treat a disease known as acromegaly, which is caused by the body producing so much of a natural compound known as growth hormone. Acromegaly treatment lowers the risk of serious complications including diabetes and heart disease. Owing to Technical Progress Octreotide Acetate is now available as oral administration drug in the form of tablets and capsules.

Growth Drivers
  • Increasing Preference for Oral Octreotide Acetate over Injectables
  • Rising Geriatric Population
  • Prevalence of Chronic Health Disorders

Market Trends
  • Technical Progress in Medical Industry

Roadblocks
  • Complementary Products

Opportunities
  • Unexplored Markets
  • Heavy Investments in Healthcare Research & Development

Challenges
  • Side Effects and Adverse Reactions
  • Regulatory Approval


Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Novartis (Switzerland), Chiasma Pharma (United States), Sun Pharmaceutical Industries (India), Neiss Labs (India), Unique Chemicals (India), Samarth Life Sciences Private Limited (India), Yipubishan (China), MITS Healthcare Private Limited (India), CELON Labs (India), HealthCare Pharma (India) and Troikaa Pharmaceuticals (India). Analyst at AMA Research see Indian Players to retain maximum share of Global Octreotide Acetate market by 2026. Considering Market by Form, the sub-segment i.e. Injectable will boost the Octreotide Acetate market. Considering Market by End Use, the sub-segment i.e. Hospital will boost the Octreotide Acetate market.

On 26th June, 2020 - Chiasma Announced FDA Approval for its “MYCAPSSA” (Octreotide Acetate) Capsules. MYCAPSSA is the First and Only Oral Somatostatin Analog and is Indicated for Long-Term Maintenance Treatment in Acromegaly Patients.

United States, Food and Drug Administration “Octreotide Acetate” Guidance; Provides a Comprehensive List of Procedures Regarding the Usage, Indications and Dosage Requirements Based on the Patient Profile of Octreotide Acetate Injections Across US. and European Medicines Agency “Octreotide Acetate Product-Specific Bioequivalence Guidance” - provides product-specific instructions for demonstrating bioequivalence of octreotide acetate depot powder and solvent for injection (10 mg, 20 mg, or 30 mg).

What Can be Explored with the Octreotide Acetate Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Octreotide Acetate Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Octreotide Acetate
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Octreotide Acetate market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Octreotide Acetate market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Octreotide Acetate Drug Manufactures, API Providers, Octreotide Acetate Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Immediate-release Injection Form
  • LAR Depot Form
By Application
  • Medical Therapeutic
  • Medical Prophylactic
By Form
  • Injectable
  • Tablets
  • Capsules
  • Others

By End Use
  • Hospital
  • Specialty Clinic

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Preference for Oral Octreotide Acetate over Injectables
      • 3.2.2. Rising Geriatric Population
      • 3.2.3. Prevalence of Chronic Health Disorders
    • 3.3. Market Challenges
      • 3.3.1. Side Effects and Adverse Reactions
      • 3.3.2. Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Octreotide Acetate, by Type, Application, Form, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Octreotide Acetate (Value)
      • 5.2.1. Global Octreotide Acetate by: Type (Value)
        • 5.2.1.1. Immediate-release Injection Form
        • 5.2.1.2. LAR Depot Form
      • 5.2.2. Global Octreotide Acetate by: Application (Value)
        • 5.2.2.1. Medical Therapeutic
        • 5.2.2.2. Medical Prophylactic
      • 5.2.3. Global Octreotide Acetate by: Form (Value)
        • 5.2.3.1. Injectable
        • 5.2.3.2. Tablets
        • 5.2.3.3. Capsules
        • 5.2.3.4. Others
      • 5.2.4. Global Octreotide Acetate by: End Use (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Specialty Clinic
      • 5.2.5. Global Octreotide Acetate Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Octreotide Acetate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Chiasma Pharma (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Neiss Labs (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Unique Chemicals (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Samarth Life Sciences Private Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Yipubishan (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MITS Healthcare Private Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CELON Labs (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. HealthCare Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Troikaa Pharmaceuticals (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Octreotide Acetate Sale, by Type, Application, Form, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Octreotide Acetate (Value)
      • 7.2.1. Global Octreotide Acetate by: Type (Value)
        • 7.2.1.1. Immediate-release Injection Form
        • 7.2.1.2. LAR Depot Form
      • 7.2.2. Global Octreotide Acetate by: Application (Value)
        • 7.2.2.1. Medical Therapeutic
        • 7.2.2.2. Medical Prophylactic
      • 7.2.3. Global Octreotide Acetate by: Form (Value)
        • 7.2.3.1. Injectable
        • 7.2.3.2. Tablets
        • 7.2.3.3. Capsules
        • 7.2.3.4. Others
      • 7.2.4. Global Octreotide Acetate by: End Use (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Specialty Clinic
      • 7.2.5. Global Octreotide Acetate Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Octreotide Acetate: by Type(USD Million)
  • Table 2. Octreotide Acetate Immediate-release Injection Form , by Region USD Million (2015-2020)
  • Table 3. Octreotide Acetate LAR Depot Form , by Region USD Million (2015-2020)
  • Table 4. Octreotide Acetate: by Application(USD Million)
  • Table 5. Octreotide Acetate Medical Therapeutic , by Region USD Million (2015-2020)
  • Table 6. Octreotide Acetate Medical Prophylactic , by Region USD Million (2015-2020)
  • Table 7. Octreotide Acetate: by Form(USD Million)
  • Table 8. Octreotide Acetate Injectable , by Region USD Million (2015-2020)
  • Table 9. Octreotide Acetate Tablets , by Region USD Million (2015-2020)
  • Table 10. Octreotide Acetate Capsules , by Region USD Million (2015-2020)
  • Table 11. Octreotide Acetate Others , by Region USD Million (2015-2020)
  • Table 12. Octreotide Acetate: by End Use(USD Million)
  • Table 13. Octreotide Acetate Hospital , by Region USD Million (2015-2020)
  • Table 14. Octreotide Acetate Specialty Clinic , by Region USD Million (2015-2020)
  • Table 15. South America Octreotide Acetate, by Country USD Million (2015-2020)
  • Table 16. South America Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 17. South America Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 18. South America Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 19. South America Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 20. Brazil Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 21. Brazil Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 22. Brazil Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 23. Brazil Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 24. Argentina Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 25. Argentina Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 26. Argentina Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 27. Argentina Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 28. Rest of South America Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 31. Rest of South America Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 32. Asia Pacific Octreotide Acetate, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 34. Asia Pacific Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 36. Asia Pacific Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 37. China Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 38. China Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 39. China Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 40. China Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 41. Japan Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 42. Japan Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 43. Japan Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 44. Japan Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 45. India Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 46. India Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 47. India Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 48. India Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 49. South Korea Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 50. South Korea Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 51. South Korea Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 52. South Korea Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 53. Taiwan Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 54. Taiwan Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 55. Taiwan Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 56. Taiwan Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 57. Australia Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 58. Australia Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 59. Australia Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 60. Australia Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 65. Europe Octreotide Acetate, by Country USD Million (2015-2020)
  • Table 66. Europe Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 67. Europe Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 68. Europe Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 69. Europe Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 70. Germany Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 71. Germany Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 72. Germany Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 73. Germany Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 74. France Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 75. France Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 76. France Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 77. France Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 78. Italy Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 79. Italy Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 80. Italy Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 81. Italy Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 82. United Kingdom Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 83. United Kingdom Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 84. United Kingdom Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 85. United Kingdom Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 86. Netherlands Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 87. Netherlands Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 88. Netherlands Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 89. Netherlands Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 90. Rest of Europe Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 91. Rest of Europe Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 92. Rest of Europe Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 93. Rest of Europe Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 94. MEA Octreotide Acetate, by Country USD Million (2015-2020)
  • Table 95. MEA Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 96. MEA Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 97. MEA Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 98. MEA Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 99. Middle East Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 100. Middle East Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 101. Middle East Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 102. Middle East Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 103. Africa Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 104. Africa Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 105. Africa Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 106. Africa Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 107. North America Octreotide Acetate, by Country USD Million (2015-2020)
  • Table 108. North America Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 109. North America Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 110. North America Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 111. North America Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 112. United States Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 113. United States Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 114. United States Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 115. United States Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 116. Canada Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 117. Canada Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 118. Canada Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 119. Canada Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 120. Mexico Octreotide Acetate, by Type USD Million (2015-2020)
  • Table 121. Mexico Octreotide Acetate, by Application USD Million (2015-2020)
  • Table 122. Mexico Octreotide Acetate, by Form USD Million (2015-2020)
  • Table 123. Mexico Octreotide Acetate, by End Use USD Million (2015-2020)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Octreotide Acetate: by Type(USD Million)
  • Table 136. Octreotide Acetate Immediate-release Injection Form , by Region USD Million (2021-2026)
  • Table 137. Octreotide Acetate LAR Depot Form , by Region USD Million (2021-2026)
  • Table 138. Octreotide Acetate: by Application(USD Million)
  • Table 139. Octreotide Acetate Medical Therapeutic , by Region USD Million (2021-2026)
  • Table 140. Octreotide Acetate Medical Prophylactic , by Region USD Million (2021-2026)
  • Table 141. Octreotide Acetate: by Form(USD Million)
  • Table 142. Octreotide Acetate Injectable , by Region USD Million (2021-2026)
  • Table 143. Octreotide Acetate Tablets , by Region USD Million (2021-2026)
  • Table 144. Octreotide Acetate Capsules , by Region USD Million (2021-2026)
  • Table 145. Octreotide Acetate Others , by Region USD Million (2021-2026)
  • Table 146. Octreotide Acetate: by End Use(USD Million)
  • Table 147. Octreotide Acetate Hospital , by Region USD Million (2021-2026)
  • Table 148. Octreotide Acetate Specialty Clinic , by Region USD Million (2021-2026)
  • Table 149. South America Octreotide Acetate, by Country USD Million (2021-2026)
  • Table 150. South America Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 151. South America Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 152. South America Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 153. South America Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 154. Brazil Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 155. Brazil Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 156. Brazil Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 157. Brazil Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 158. Argentina Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 159. Argentina Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 160. Argentina Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 161. Argentina Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 162. Rest of South America Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 163. Rest of South America Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 164. Rest of South America Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 165. Rest of South America Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 166. Asia Pacific Octreotide Acetate, by Country USD Million (2021-2026)
  • Table 167. Asia Pacific Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 168. Asia Pacific Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 170. Asia Pacific Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 171. China Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 172. China Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 173. China Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 174. China Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 175. Japan Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 176. Japan Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 177. Japan Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 178. Japan Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 179. India Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 180. India Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 181. India Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 182. India Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 183. South Korea Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 184. South Korea Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 185. South Korea Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 186. South Korea Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 187. Taiwan Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 188. Taiwan Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 189. Taiwan Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 190. Taiwan Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 191. Australia Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 192. Australia Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 193. Australia Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 194. Australia Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 199. Europe Octreotide Acetate, by Country USD Million (2021-2026)
  • Table 200. Europe Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 201. Europe Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 202. Europe Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 203. Europe Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 204. Germany Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 205. Germany Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 206. Germany Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 207. Germany Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 208. France Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 209. France Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 210. France Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 211. France Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 212. Italy Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 213. Italy Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 214. Italy Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 215. Italy Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 216. United Kingdom Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 217. United Kingdom Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 218. United Kingdom Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 219. United Kingdom Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 220. Netherlands Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 221. Netherlands Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 222. Netherlands Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 223. Netherlands Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 224. Rest of Europe Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 225. Rest of Europe Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 226. Rest of Europe Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 227. Rest of Europe Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 228. MEA Octreotide Acetate, by Country USD Million (2021-2026)
  • Table 229. MEA Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 230. MEA Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 231. MEA Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 232. MEA Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 233. Middle East Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 234. Middle East Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 235. Middle East Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 236. Middle East Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 237. Africa Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 238. Africa Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 239. Africa Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 240. Africa Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 241. North America Octreotide Acetate, by Country USD Million (2021-2026)
  • Table 242. North America Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 243. North America Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 244. North America Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 245. North America Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 246. United States Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 247. United States Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 248. United States Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 249. United States Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 250. Canada Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 251. Canada Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 252. Canada Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 253. Canada Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 254. Mexico Octreotide Acetate, by Type USD Million (2021-2026)
  • Table 255. Mexico Octreotide Acetate, by Application USD Million (2021-2026)
  • Table 256. Mexico Octreotide Acetate, by Form USD Million (2021-2026)
  • Table 257. Mexico Octreotide Acetate, by End Use USD Million (2021-2026)
  • Table 258. Research Programs/Design for This Report
  • Table 259. Key Data Information from Secondary Sources
  • Table 260. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Octreotide Acetate: by Type USD Million (2015-2020)
  • Figure 5. Global Octreotide Acetate: by Application USD Million (2015-2020)
  • Figure 6. Global Octreotide Acetate: by Form USD Million (2015-2020)
  • Figure 7. Global Octreotide Acetate: by End Use USD Million (2015-2020)
  • Figure 8. South America Octreotide Acetate Share (%), by Country
  • Figure 9. Asia Pacific Octreotide Acetate Share (%), by Country
  • Figure 10. Europe Octreotide Acetate Share (%), by Country
  • Figure 11. MEA Octreotide Acetate Share (%), by Country
  • Figure 12. North America Octreotide Acetate Share (%), by Country
  • Figure 13. Global Octreotide Acetate share by Players 2020 (%)
  • Figure 14. Global Octreotide Acetate share by Players (Top 3) 2020(%)
  • Figure 15. Global Octreotide Acetate share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 19. Chiasma Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 20. Chiasma Pharma (United States) Revenue: by Geography 2020
  • Figure 21. Sun Pharmaceutical Industries (India) Revenue, Net Income and Gross profit
  • Figure 22. Sun Pharmaceutical Industries (India) Revenue: by Geography 2020
  • Figure 23. Neiss Labs (India) Revenue, Net Income and Gross profit
  • Figure 24. Neiss Labs (India) Revenue: by Geography 2020
  • Figure 25. Unique Chemicals (India) Revenue, Net Income and Gross profit
  • Figure 26. Unique Chemicals (India) Revenue: by Geography 2020
  • Figure 27. Samarth Life Sciences Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 28. Samarth Life Sciences Private Limited (India) Revenue: by Geography 2020
  • Figure 29. Yipubishan (China) Revenue, Net Income and Gross profit
  • Figure 30. Yipubishan (China) Revenue: by Geography 2020
  • Figure 31. MITS Healthcare Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 32. MITS Healthcare Private Limited (India) Revenue: by Geography 2020
  • Figure 33. CELON Labs (India) Revenue, Net Income and Gross profit
  • Figure 34. CELON Labs (India) Revenue: by Geography 2020
  • Figure 35. HealthCare Pharma (India) Revenue, Net Income and Gross profit
  • Figure 36. HealthCare Pharma (India) Revenue: by Geography 2020
  • Figure 37. Troikaa Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 38. Troikaa Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 39. Global Octreotide Acetate: by Type USD Million (2021-2026)
  • Figure 40. Global Octreotide Acetate: by Application USD Million (2021-2026)
  • Figure 41. Global Octreotide Acetate: by Form USD Million (2021-2026)
  • Figure 42. Global Octreotide Acetate: by End Use USD Million (2021-2026)
  • Figure 43. South America Octreotide Acetate Share (%), by Country
  • Figure 44. Asia Pacific Octreotide Acetate Share (%), by Country
  • Figure 45. Europe Octreotide Acetate Share (%), by Country
  • Figure 46. MEA Octreotide Acetate Share (%), by Country
  • Figure 47. North America Octreotide Acetate Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis (Switzerland)
  • Chiasma Pharma (United States)
  • Sun Pharmaceutical Industries (India)
  • Neiss Labs (India)
  • Unique Chemicals (India)
  • Samarth Life Sciences Private Limited (India)
  • Yipubishan (China)
  • MITS Healthcare Private Limited (India)
  • CELON Labs (India)
  • HealthCare Pharma (India)
  • Troikaa Pharmaceuticals (India)
Select User Access Type

Key Highlights of Report


Apr 2021 233 Pages 54 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Octreotide Acetate Quantitative research analysis
Global Octreotide Acetate Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Octreotide Acetate Report?

Have a Query? Click Here

Other Related Reports

Vasodilators Comprehensive Study by Type (Arterial Dilators, Venous Dilators, Mixed Dilators), Application (Hypertension, Angina, Heart Failure), Drug Type (Hydralazine, ACE inhibitors, Minoxidil), D...
$ 3650
Cell Isolation/Cell Separation Comprehensive Study by Type (Reagent, Instrument, Others), Application (Biomolecule Isolation, Cancer Research, Stem Cell Research, Tissue Regeneration & Regenerative M...
$ 3750
Psoriasis Treatment Comprehensive Study by Type (Psoriatic Arthritis, Plaque Psoriasis, Others), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Hospital Pharmacies, Online...
$ 3800
Beta blockers Comprehensive Study by Type (Non-selective antagonists, Selective β1-antagonists), Application (Abnormal Heart Rhythms, Hypertension), Generation (1st Generation, 2nd Generation, 3...
$ 3400
Narcolepsy Treatment Comprehensive Study by Type (Sodium Oxybate, Antidepressants, Central Nervous System Stimulants, Others), Application (Primary Narcolepsy with Cataplexy, Primary Narcolepsy witho...
$ 3750
Biosimilar Drug Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal A...
$ 3750